These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29352520)

  • 21. Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents.
    Tahara A; Takasu T
    Life Sci; 2018 Mar; 197():80-90. PubMed ID: 29425766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
    Hayashizaki-Someya Y; Kurosaki E; Takasu T; Mitori H; Yamazaki S; Koide K; Takakura S
    Eur J Pharmacol; 2015 May; 754():19-24. PubMed ID: 25701721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renoprotective effects of empagliflozin in high-fat diet-induced obesity-related glomerulopathy by regulation of gut-kidney axis.
    Lei L; Zhu T; Cui TJ; Liu Y; Hocher JG; Chen X; Zhang XM; Cai KW; Deng ZY; Wang XH; Tang C; Lin L; Reichetzeder C; Zheng ZH; Hocher B; Lu YP
    Am J Physiol Cell Physiol; 2024 Oct; 327(4):C994-C1011. PubMed ID: 39183639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice.
    Okuma H; Mori K; Nakamura S; Sekine T; Ogawa Y; Tsuchiya K
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
    Nishimura N; Kitade M; Noguchi R; Namisaki T; Moriya K; Takeda K; Okura Y; Aihara Y; Douhara A; Kawaratani H; Asada K; Yoshiji H
    J Gastroenterol; 2016 Dec; 51(12):1141-1149. PubMed ID: 27025708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term control of diet affects cisplatin-induced acute kidney injury through modulation of mitochondrial dynamics and mitochondrial GSH.
    Kim JS; Han YK; Kong MJ; Park KM
    Physiol Rep; 2022 Jun; 10(12):e15348. PubMed ID: 35748040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
    Tahara A; Takasu T
    Eur J Pharmacol; 2018 Jul; 830():68-75. PubMed ID: 29702076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
    Honda Y; Imajo K; Kato T; Kessoku T; Ogawa Y; Tomeno W; Kato S; Mawatari H; Fujita K; Yoneda M; Saito S; Nakajima A
    PLoS One; 2016; 11(1):e0146337. PubMed ID: 26731267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro.
    Wei D; Liao L; Wang H; Zhang W; Wang T; Xu Z
    Life Sci; 2020 Apr; 247():117414. PubMed ID: 32035928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.
    Tahara A
    Eur J Pharmacol; 2021 Jun; 901():174076. PubMed ID: 33798599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of tubular damage in high-fat-diet-fed obese mice using sodium-glucose co-transporter inhibitors.
    Saitoh S; Takaki T; Nakajima K; Wo B; Terashima H; Shimo S; Nguyen HB; Thai TQ; Kumamoto K; Kunisawa K; Nagao S; Tojo A; Ohno N; Takahashi K
    PLoS One; 2023; 18(2):e0281770. PubMed ID: 36780539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak L; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2021-2033. PubMed ID: 29572114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
    Schwartz SL; Akinlade B; Klasen S; Kowalski D; Zhang W; Wilpshaar W
    Diabetes Technol Ther; 2011 Dec; 13(12):1219-27. PubMed ID: 21854192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
    Masuda T; Muto S; Fukuda K; Watanabe M; Ohara K; Koepsell H; Vallon V; Nagata D
    Physiol Rep; 2020 Jan; 8(2):e14360. PubMed ID: 31994353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).
    Miura H; Sakaguchi K; Okada Y; Yamada T; Otowa-Suematsu N; So A; Komada H; Hirota Y; Ohara T; Kuroki Y; Hara K; Matsuda T; Kishi M; Takeda A; Yokota K; Tamori Y; Ogawa W
    J Diabetes Investig; 2019 Sep; 10(5):1254-1261. PubMed ID: 30688412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Silymarin protects against renal injury through normalization of lipid metabolism and mitochondrial biogenesis in high fat-fed mice.
    Bin Feng ; Meng R; Bin Huang ; Bi Y; Shen S; Zhu D
    Free Radic Biol Med; 2017 Sep; 110():240-249. PubMed ID: 28625483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
    Tahara A; Takasu T
    Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
    [No Abstract]   [Full Text] [Related]  

  • 40. Dapagliflozin Ameliorates Ovulation Disorders via Attenuating Activated Microglia-Mediated Hypothalamic Inflammation in HFD-Fed Mice.
    Chen X; Xiao Z; Liu Q; Luo D; Cai Y; Fan M
    Neuroendocrinology; 2024; 114(4):331-347. PubMed ID: 38147832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.